1. Home
  2. AYI vs IMVT Comparison

AYI vs IMVT Comparison

Compare AYI & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acuity Brands Inc.

AYI

Acuity Brands Inc.

HOLD

Current Price

$306.06

Market Cap

9.6B

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$34.54

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AYI
IMVT
Founded
2001
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Building Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
8.5B
IPO Year
2001
2019

Fundamental Metrics

Financial Performance
Metric
AYI
IMVT
Price
$306.06
$34.54
Analyst Decision
Buy
Buy
Analyst Count
6
8
Target Price
$369.17
$33.00
AVG Volume (30 Days)
206.2K
1.1M
Earning Date
04-02-2026
05-28-2026
Dividend Yield
0.28%
N/A
EPS Growth
N/A
N/A
EPS
11.45
N/A
Revenue
$3,461,000,000.00
N/A
Revenue This Year
$7.51
N/A
Revenue Next Year
$5.14
N/A
P/E Ratio
$27.14
N/A
Revenue Growth
4.05
N/A
52 Week Low
$257.04
$15.22
52 Week High
$380.17
$45.42

Technical Indicators

Market Signals
Indicator
AYI
IMVT
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
AYI
IMVT

About AYI Acuity Brands Inc.

Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. It designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: